Clinical trial
A Long-Term, Open-Label, Phase 3a Safety Study of Oral TAK-559 (32 mg QD) in the Treatment of Patients With Type 2 Diabetes Mellitus
NCT00762112 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Long-Term, Open-Label, Phase 3a Safety Study of Oral TAK-559 (32 mg QD) in the Treatment of Patients With Type 2 Diabetes Mellitus
- Lead sponsor
- Takeda
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 30, 2003
- Completion date
- December 31, 2004
- Enrollment
- 316 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.